|
|
 |
|
Viewing report
|
|
|
|
Current Drug Development Market for Cytokines, Chemokines and Growth Factors
Drug and Market Development Publishing, Jan 2007, Pages: 233
Our Current Drug Development Market for Cytokines, Chemokines and Growth Factors focuses primarily on the cytokine market, company pipelines and trials in the field of cytokine research. This report succinctly details all the latest advances in the push to market of cytokine-based therapeutics: which products have evolved, which have failed and new players on the field. Primary readers will have comprehensive updates on relevant company pipelines.
Unique to this report is the comprehensive nature of compiled biological response modifiers currently in clinical testing. From the many interleukins to the vast array of growth factors, most all currently developed monoclonals, diabodies, soluble receptors, vaccines, small molecule antagonists, peptide mimetics, recombinantly altered antigens, as well as RNA interference and gene therapy vectors and plasmids are covered.
Also unique is the easy reference tables provided for 'at-a-glance' assessment of developmental pipeline progress.
Market projection
The authors estimate that 2008 biopharma sales statistics covering cytokines will be in the range of:
- Total world market, in terms of corporate revenues from biopharmaceutical sales, is probably about $80 - 100 billion
- The largest portion of sales, of about 50 - 60% involves recombinant proteins, including recombinant monoclonal antibodies. Interferon cytokine's sales alone currently account for $1billion in revenues and is forecast to reach $3.5 billion by the end of the decade. This represents a dramatic 75% increase in 2005 market estimates
- Other major sectors in terms of sales are vaccines ($15 billion), and human plasma-derived proteins (~$10 billion), with all other biopharmaceuticals accounting for $10 or more billion in sales
- There could well be another $5 billion in sales of miscellaneous biosimilars, as older cytokine recombinant patents expire
Overall, cytokine-based drug sales seem to account for ~20% of the world biopharmaceutical market
Report Benefits
- Identify which companies continue to leverage cytokine-based drugs and which companies license off developed cytokine technologies
- Examine details on which small biotech start-up R&D pipelines are seeking big pharma development on a cytokine to cytokine basis
- Explore products that continue to advance in the FDA approval cycle, seeking expanded label-uses
- Research novel and newly discovered cytokine applications and pathways, which are highlighted to facilitate future drug discovery.
Start-up ventures are given a firm footing in the vast landscape of cytokine drug discovery and development and big pharma will be informed as to which of the many small biotech companies may meet their partnering or acquisition needs.
About the Author
Jeffery Terryberry has over a dozen peer-reviewed publications in Clinical Chemistry research. Current areas of focus include orthobiologic drug development utilizing osteoinductive peptides, monoclonal antibody production and immunogenicity, and the phytochemistry of novel herbal medicines. Gautam Thor received his PhD in Neurobiology. He has researched at UCSD in the field of Neuroimmunology and is the author of numerous scientific and medical publications through NeuroConsultants, and, is internationally recognized for his expertise in human diagnostics.
Product samples
Samples for this product is available. Please Login/Register to download these samples.
Customers who bought this item also bought
Cytokines, Chemokines, and Growth Factors- Key Targets for Immunotherapeutic Development
Cytokine Therapeutics: Current and Future Markets in Inflammatory Disease
Gene Therapy - Technologies, Markets and Companies
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Competition For The Anti-TNF Failure Patient Population Increases
Neuroprotection - Drugs, Markets and Companies
Pain Therapeutics - Drugs, Markets and Companies
Competitor Analysis: Interferon
Drug Delivery in Cancer - Technologies, Markets and Companies
Alzheimer Disease - New Drugs, Markets and Companies
GPCR - Drug Targets
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Nuclear Receptors in Drug Metabolism
|
|
|
|
